These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9734197

  • 1. [If I were to wake-up clumsy and trembling...(or how to begin treatment of Parkinson disease].
    Linazasoro G.
    Neurologia; 1998; 13(6):265-70. PubMed ID: 9734197
    [No Abstract] [Full Text] [Related]

  • 2. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B, Montastruc JL.
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract] [Full Text] [Related]

  • 3. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R, Swedish Parkinson Study Group.
    Neurology; 2006 Apr 25; 66(8):1200-6. PubMed ID: 16540603
    [Abstract] [Full Text] [Related]

  • 4. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS, Fazzini E, Volkow ND.
    Ann Neurol; 1996 Aug 25; 40(2):267-8. PubMed ID: 8773616
    [No Abstract] [Full Text] [Related]

  • 5. Treatment challenges in early stage Parkinson's disease.
    Tetrud J.
    Neurol Clin; 2004 Oct 25; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
    Aaltonen H, Kilkku O, Heinonen E, Mäki-Ikola O.
    BMJ; 1998 Dec 05; 317(7172):1586-7. PubMed ID: 9890764
    [No Abstract] [Full Text] [Related]

  • 11. [Parkinson disease].
    Moore AP, Clarke CE.
    Praxis (Bern 1994); 2001 Jun 07; 90(23):1041-6. PubMed ID: 11447724
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Selegiline and excess mortality.
    Oakes D.
    Clin Neuropharmacol; 1997 Dec 07; 20(6):542. PubMed ID: 9403228
    [No Abstract] [Full Text] [Related]

  • 14. Levodopa therapy for Parkinson's disease: challenges and future prospects.
    Olanow CW, Lees A, Obeso J.
    Mov Disord; 2008 Dec 07; 23 Suppl 3():S495-6. PubMed ID: 18781670
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Parkinson's disease.
    Clarke C, Moore AP.
    Clin Evid; 2002 Jun 07; (7):1208-20. PubMed ID: 12230738
    [No Abstract] [Full Text] [Related]

  • 17. Parkinson's disease.
    Imke S.
    Adv Nurse Pract; 1998 Jan 07; 6(1):24-8. PubMed ID: 9495941
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Levodopa unresponsive symptoms in Parkinson disease.
    Sethi K.
    Mov Disord; 2008 Jan 07; 23 Suppl 3():S521-33. PubMed ID: 18781679
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.